{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:38:20Z","timestamp":1782970700679,"version":"3.54.5"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is estimated to affect 38% of the global population, with limited options for treatment. It could progress to metabolic-associated steatohepatitis (MASH), fibrosis, and hepatocellular carcinoma. Agonists for farnesoid X receptor (FXR), peroxisome proliferation-associated receptors (PPARs), and sirtuin1 (SIRT1) are currently investigated for MASLD treatment. The subcellular localization of those proteins was shown to affect their function and could possibly be affected by different metabolites. Moreover, while those protein targets were found to be affected by the gut microbiome in mice, they have not yet been investigated in humans. Existing evidence independently links the gut microbiome to MASLD onset and demonstrates that host proteins are impacted by the microbiome. Therefore, we aimed at using integrative multi-omics analysis to investigate the interrelationship between the gut microbiome, fecal and serum metabolomes, and those selected protein targets in a cohort of patients with MASLD to identify potential markers differentiating MASLD and MASH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum and stool samples were collected from patients with MASLD and healthy controls, while formalin-fixed paraffin-embedded (FFPE) liver biopsies and clinical laboratory tests were obtained from patients only. Expression of the protein targets was analyzed by immunohistochemistry (IHC). Microbiome and metabolome analyses were performed, followed by bioinformatics, correlation, and multivariate and integrated multi-omics analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SIRT1 and FXR subcellular localizations were correlated with multiple bacteria and metabolites, respectively. Three genera (\n                      <jats:italic>Rothia<\/jats:italic>\n                      ,\n                      <jats:italic>Haemophilus<\/jats:italic>\n                      , and\n                      <jats:italic>Acetatifactor<\/jats:italic>\n                      ) correlated with NAFLD activity score (NAS), and a signature of 20 bacterial genera, 10 fecal and 30 serum metabolites, and 3 host proteins differentiated between MASLD and MASH. Moreover, in silico analysis suggested myristic, lauric, octanoic, and nonanoic acids to putatively affect peroxisome proliferator-activated receptor alpha (PPARA) and FXR, and\n                      <jats:italic>Coprobacter<\/jats:italic>\n                      as an important contributor in our multi-omics model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data suggest bacteria and metabolites which potentially affect the subcellular localization, and hence activity, of anti-lipogenic proteins in MASLD patients. We also propose novel discriminatory markers between MASLD and MASH. Our findings form the groundwork for future mechanistic studies of both host and microbial factors possibly contributing to the multifaceted disease outcome and offer potential diagnostic markers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmolb.2026.1703547","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:25:41Z","timestamp":1782966341000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between the subcellular localization of host proteins and gut microbiome and metabolome in metabolic dysfunction-associated steatotic liver disease: a pilot study"],"prefix":"10.3389","volume":"13","author":[{"given":"Shereen A.","family":"El Sobky","sequence":"first","affiliation":[{"name":"School of Medicine, Newgiza University (NGU)","place":["Giza, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"El-Ekiaby","sequence":"additional","affiliation":[{"name":"School of Medicine, Newgiza University (NGU)","place":["Giza, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Injie O.","family":"Fawzy","sequence":"additional","affiliation":[{"name":"School of Medicine, Newgiza University (NGU)","place":["Giza, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira Khaled","family":"Abdelhamid","sequence":"additional","affiliation":[{"name":"School of Medicine, Newgiza University (NGU)","place":["Giza, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Attia","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University","place":["Cairo, Egypt"]},{"name":"Center for Genome and Microbiome Research, Faculty of Pharmacy, Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim H.","family":"Fayed","sequence":"additional","affiliation":[{"name":"School of Medicine, Newgiza University (NGU)","place":["Giza, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Badr","sequence":"additional","affiliation":[{"name":"School of Medicine, Newgiza University (NGU)","place":["Giza, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Emadeldeen","sequence":"additional","affiliation":[{"name":"Hepatology and Gastroenterology Department, National Hepatology and Tropical Medicine Research Institute","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Nagy","sequence":"additional","affiliation":[{"name":"School of Medicine, Newgiza University (NGU)","place":["Giza, Egypt"]},{"name":"Kasr Al-Ainy Viral Hepatitis Center (KAVHC), Kasr Al-Ainy University Hospital, Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Negm","sequence":"additional","affiliation":[{"name":"School of Medicine, Newgiza University (NGU)","place":["Giza, Egypt"]},{"name":"Clinical and Research Center for Intestinal Disorders, Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Sherif","family":"Negm","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Moustafa","sequence":"additional","affiliation":[{"name":"Biotechnology Graduate Program, American University in Cairo","place":["New Cairo, Egypt"]},{"name":"Department of Biology, American University in Cairo","place":["New Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Kassas","sequence":"additional","affiliation":[{"name":"Endemic Medicine Department, Faculty of Medicine, Capital University (Formerly Helwan University)","place":["Cairo, Egypt"]},{"name":"Steatotic Liver Diseases Study Foundation in Middle East and North Africa (SLMENA)","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Farag","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, Faculty of Pharmacy, Cairo University","place":["Cairo, Egypt"]},{"name":"Healthcare Faculty, Saxony Egypt University (SEU)","place":["Badr City, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy K.","family":"Aziz","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University","place":["Cairo, Egypt"]},{"name":"Center for Genome and Microbiome Research, Faculty of Pharmacy, Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed I.","family":"Abdelaziz","sequence":"additional","affiliation":[{"name":"School of Medicine, Newgiza University (NGU)","place":["Giza, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/antiox12081487","article-title":"The potential effects of quercetin-loaded nanoliposomes on amoxicillin\/clavulanate-induced hepatic damage: targeting the SIRT1\/Nrf2\/NF-kappaB signaling pathway and microbiota modulation","volume":"12","author":"Abd El-Emam","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.molcel.2011.07.028","article-title":"A biotin switch-based proteomics approach identifies 14-3-3zeta as a target of Sirt1 in the metabolic regulation of caspase-2","volume":"43","author":"Andersen","year":"2011","journal-title":"Mol. Cell."},{"key":"B3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.phrs.2017.10.009","article-title":"Microalgae-derived oxylipins decrease inflammatory mediators by regulating the subcellular location of NFkappaB and PPAR-gamma","volume":"128","author":"Avila-Roman","year":"2018","journal-title":"Pharmacol. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"166097","DOI":"10.1016\/j.bbadis.2021.166097","article-title":"PPARs in liver physiology","volume":"1867","author":"Berthier","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/genes14040857","article-title":"Human genes involved in the interaction between host and gut microbiome: regulation and pathogenic mechanisms","volume":"14","author":"Boccuto","year":"2023","journal-title":"Genes (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7150\/ijbs.6.599","article-title":"Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K\/IGF-1R signaling in human cancer cells","volume":"6","author":"Byles","year":"2010","journal-title":"Int. J. Biol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"632864","DOI":"10.3389\/fimmu.2021.632864","article-title":"Bile acids elevated in chronic periaortitis could activate farnesoid-X-receptor to suppress IL-6 production by macrophages","volume":"12","author":"Cao","year":"2021","journal-title":"Front. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1700903","DOI":"10.1002\/mnfr.201700903","article-title":"Sugary kefir strain Lactobacillus Mali APS1 ameliorated hepatic steatosis by regulation of SIRT-1\/Nrf-2 and gut microbiota in rats","volume":"62","author":"Chen","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.apsb.2022.08.019","article-title":"SIRT1 activation synergizes with FXR agonism in hepatoprotection via governing nucleocytoplasmic shuttling and degradation of FXR","volume":"13","author":"Cui","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"B13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/bs.pmbts.2020.04.006","article-title":"Diet, nutrients and the microbiome","volume":"171","author":"Dahl","year":"2020","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1136\/bmjnph-2020-000202","article-title":"Evaluation of different stool extraction methods for metabolomics measurements in human faecal samples","volume":"4","author":"Erben","year":"2021","journal-title":"BMJ Nutr. Prev. Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.3390\/molecules26113341","article-title":"The stool volatile metabolome of pre-term babies","volume":"26","author":"Frau","year":"2021","journal-title":"Molecules"},{"key":"B16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/pathogens3010014","article-title":"Metabolism of cholesterol and bile acids by the gut microbiota","volume":"3","author":"Gerard","year":"2013","journal-title":"Pathogens"},{"key":"B17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1159\/000510600","article-title":"Lipoprotein and metabolic profiles indicate similar cardiovascular risk of liver steatosis and NASH","volume":"102","author":"Gottlieb","year":"2021","journal-title":"Digestion"},{"key":"B18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41430-019-0466-1","article-title":"Pretreatment Prevotella-to-Bacteroides ratio and markers of glucose metabolism as prognostic markers for dietary weight loss maintenance","volume":"74","author":"Hjorth","year":"2020","journal-title":"Eur. J. Clin. Nutr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"20015","DOI":"10.1074\/jbc.M802187200","article-title":"SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase","volume":"283","author":"Hou","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","article-title":"Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women","volume":"24","author":"Hoyles","year":"2018","journal-title":"Nat. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"802","DOI":"10.14218\/JCTH.2024.00123","article-title":"Pipeline of new drug treatment for non-alcoholic fatty liver disease\/metabolic dysfunction-associated steatotic liver disease","volume":"12","author":"Hu","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/s0306-3623(98)00029-9","article-title":"Mechanisms of peroxisome proliferation by perfluorooctanoic acid and endogenous fatty acids","volume":"31","author":"Intrasuksri","year":"1998","journal-title":"Gen. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ni1018","article-title":"Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA","volume":"5","author":"Kelly","year":"2004","journal-title":"Nat. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1007\/s00018-019-03114-4","article-title":"Persistent changes in liver methylation and microbiome composition following reversal of diet-induced non-alcoholic-fatty liver disease","volume":"76","author":"Kim","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3390\/foods11162529","article-title":"Sargassum thunbergii extract attenuates high-fat diet-induced obesity in mice by modulating AMPK activation and the gut microbiota","volume":"11","author":"Kim","year":"2022","journal-title":"Foods"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","article-title":"Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice","volume":"62","author":"Le Roy","year":"2013","journal-title":"Gut"},{"key":"B29","doi-asserted-by":"publisher","first-page":"858192","DOI":"10.3389\/fmicb.2022.858192","article-title":"A novel bacterium, Butyricimonas virosa, preventing HFD-induced diabetes and metabolic disorders in mice via GLP-1 receptor","volume":"13","author":"Lee","year":"2022","journal-title":"Front. Microbiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1700738","DOI":"10.1002\/mnfr.201700738","article-title":"Tomato powder inhibits hepatic steatosis and inflammation potentially through restoring SIRT1 activity and adiponectin function independent of carotenoid cleavage enzymes in mice","volume":"62","author":"Li","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12944-021-01440-w","article-title":"Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Lipids Health Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"103248","DOI":"10.1016\/j.pmedr.2025.103248","article-title":"Global burden of metabolic dysfunction-associated steatotic liver disease from 1990 to 2021 and the prediction for the next 10 years","volume":"59","author":"Lin","year":"2025","journal-title":"Prev. Med. Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"452","DOI":"10.14218\/JCTH.2022.00089","article-title":"Intestinal barrier function in the pathogenesis of nonalcoholic fatty liver disease","volume":"11","author":"Liu","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1017\/erm.2022.42","article-title":"Lactate, histone lactylation and cancer hallmarks","volume":"25","author":"Lv","year":"2023","journal-title":"Expert Rev. Mol. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1133991","DOI":"10.3389\/fendo.2023.1133991","article-title":"Blood lactate levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease in type 2 diabetes: a real-world study","volume":"14","author":"Ma","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1802866","DOI":"10.1080\/19490976.2020.1802866","article-title":"Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health","volume":"12","author":"Mukherjee","year":"2020","journal-title":"Gut Microbes"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1242\/dmm.017400","article-title":"How informative is the mouse for human gut microbiota research?","volume":"8","author":"Nguyen","year":"2015","journal-title":"Dis. Model Mech."},{"key":"B39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.14218\/JCTH.2022.00415","article-title":"Akkermansia muciniphila and Bifidobacterium bifidum prevent NAFLD by regulating FXR expression and gut microbiota","volume":"11","author":"Nian","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/path.6330","article-title":"Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease","volume":"264","author":"Nunez-Sanchez","year":"2024","journal-title":"J. Pathol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41598-023-27885-w","article-title":"The identification of metabolites from gut microbiota in NAFLD via network pharmacology","volume":"13","author":"Oh","year":"2023","journal-title":"Sci. Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/nu12113379","article-title":"Inositol and non-alcoholic fatty liver disease: a systematic review on deficiencies and supplementation","volume":"12","author":"Pani","year":"2020","journal-title":"Nutrients"},{"key":"B43","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3389\/fimmu.2020.00906","article-title":"The genus alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health","volume":"11","author":"Parker","year":"2020","journal-title":"Front. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1242\/jcs.01600","article-title":"Activity and subcellular compartmentalization of peroxisome proliferator-activated receptor alpha are altered by the centrosome-associated protein CAP350","volume":"118","author":"Patel","year":"2005","journal-title":"J. Cell Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e001224","DOI":"10.1136\/bmjgast-2023-001224","article-title":"Association of metabolic dysfunction-associated fatty liver disease with gastrointestinal infections: insights from National Inpatient Sample Database","volume":"11","author":"Patel","year":"2024","journal-title":"BMJ Open Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/ijms22010433","article-title":"Role of peroxisome proliferator-activated receptors (PPARs) in trophoblast functions","volume":"22","author":"Peng","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/cells9041005","article-title":"Noninvasive diagnosis of NAFLD and NASH","volume":"9","author":"Piazzolla","year":"2020","journal-title":"Cells"},{"key":"B49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1210\/me.2002-0120","article-title":"Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor","volume":"17","author":"Pineda Torra","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ijms21218351","article-title":"The gut barrier, intestinal microbiota, and liver disease: molecular mechanisms and strategies to manage","volume":"21","author":"Plaza-Diaz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1099\/00207713-50-3-1155","article-title":"Caloramator coolhaasii sp. nov., a glutamate-degrading, moderately thermophilic anaerobe","volume":"50","author":"Plugge","year":"2000","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"33959","DOI":"10.1074\/jbc.M110.122978","article-title":"SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism","volume":"285","author":"Ponugoti","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/mnfr.201400314","article-title":"Fatty acid chain length and saturation influences PPAR\u03b1 transcriptional activation and repression in HepG2 cells","volume":"58","author":"Popeijus","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cmet.2009.02.006","article-title":"Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation","volume":"9","author":"Purushotham","year":"2009","journal-title":"Cell Metab."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.3390\/nu14193931","article-title":"Arenga pinnata resistant starch modulate gut microbiota and ameliorate intestinal inflammation in aged mice","volume":"14","author":"Ren","year":"2022","journal-title":"Nutrients"},{"key":"B56","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.plipres.2016.05.002","article-title":"Fatty acylation of proteins: the long and the short of it","volume":"63","author":"Resh","year":"2016","journal-title":"Prog. Lipid. Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/molecules23092315","article-title":"Hexanoic, octanoic and decanoic acids promote basal and insulin-induced phosphorylation of the Akt-mTOR axis and a balanced lipid metabolism in the HepG2 hepatoma cell line","volume":"23","author":"Rial","year":"2018","journal-title":"Molecules"},{"key":"B58","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann. Hepatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.3748\/wjg.v30.i23.2964","article-title":"Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease","volume":"30","author":"Rochon","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"106348","DOI":"10.1016\/j.phrs.2022.106348","article-title":"Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury","volume":"182","author":"Rodriguez-Diaz","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/biology9110346","article-title":"Lauric acid versus palmitic acid: effects on adipose tissue inflammation, insulin resistance, and non-alcoholic fatty liver disease in obesity","volume":"9","author":"Saraswathi","year":"2020","journal-title":"Biol. (Basel)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/1871520616666161031143301","article-title":"The Warburg effect and the hallmarks of cancer","volume":"17","author":"Schwartz","year":"2017","journal-title":"Anticancer Agents Med. Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/liv.15864","article-title":"Links between gut microbiome, metabolome, clinical variables and non-alcoholic fatty liver disease severity in bariatric patients","volume":"44","author":"Schwenger","year":"2024","journal-title":"Liver Int."},{"key":"B64","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1080\/15376516.2023.2301344","article-title":"Lauric acid attenuates hepato-metabolic complications and molecular alterations in high-fat diet-induced nonalcoholic fatty liver disease in rats","volume":"34","author":"Sedik","year":"2024","journal-title":"Toxicol. Mech. Methods"},{"key":"B65","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12967-020-02271-6","article-title":"Cytoplasmic PPARgamma is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers","volume":"18","author":"Shao","year":"2020","journal-title":"J. Transl. Med."},{"key":"B66","first-page":"849","article-title":"Prognostic role of SIRT1 in hepatocellular carcinoma","volume":"24","author":"Song","year":"2014","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2223330","DOI":"10.1080\/19490976.2023.2223330","article-title":"Faecal microbiota transplantation affects liver DNA methylation in non-alcoholic fatty liver disease: a multi-omics approach","volume":"15","author":"Stols-Goncalves","year":"2023","journal-title":"Gut Microbes"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.3748\/wjg.v30.i27.3290","article-title":"Targeted metabolomics study of fatty-acid metabolism in lean metabolic-associated fatty liver disease patients","volume":"30","author":"Sun","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1099\/00207713-47-3-651","article-title":"Caloramator proteoclasticus sp. Nov., a new moderately thermophilic anaerobic proteolytic bacterium","volume":"47","author":"Tarlera","year":"1997","journal-title":"Int. J. Syst. Bacteriol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"9595","DOI":"10.1007\/s11033-020-06019-9","article-title":"Lauric acid alleviates insulin resistance by improving mitochondrial biogenesis in THP-1 macrophages","volume":"47","author":"Tham","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.jhepr.2023.100780","article-title":"Role of ammonia in NAFLD: an unusual suspect","volume":"5","author":"Thomsen","year":"2023","journal-title":"JHEP Rep."},{"key":"B73","doi-asserted-by":"publisher","first-page":"107155","DOI":"10.1016\/j.phrs.2024.107155","article-title":"SIRT1: harnessing multiple pathways to hinder NAFLD","volume":"203","author":"Tian","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2021","journal-title":"Biomolecules"},{"key":"B75","doi-asserted-by":"publisher","first-page":"121","DOI":"10.14715\/cmb\/2023.69.10.17","article-title":"Deletion of the PPARdelta gene exacerbates high-fat diet-induced nonalcoholic fatty liver disease in mice through the gut-liver axis","volume":"69","author":"Wang","year":"2023","journal-title":"Cell. Mol. Biol. (Noisy-le-grand)"},{"key":"B76","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1126\/science.1208344","article-title":"Linking long-term dietary patterns with gut microbial enterotypes","volume":"334","author":"Wu","year":"2011","journal-title":"Science"},{"key":"B77","doi-asserted-by":"publisher","first-page":"111255","DOI":"10.1016\/j.biopha.2021.111255","article-title":"Crosstalk between PPARs and gut microbiota in NAFLD","volume":"136","author":"Wu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B78","doi-asserted-by":"publisher","first-page":"759306","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial","volume":"12","author":"Xue","year":"","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"951689","DOI":"10.3389\/fendo.2022.951689","article-title":"Potential screening indicators for early diagnosis of NAFLD\/MAFLD and liver fibrosis: triglyceride glucose index-related parameters","volume":"13","author":"Xue","year":"","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.3390\/nu15183970","article-title":"New insights into the pathogenesis of metabolic-associated fatty liver disease (MAFLD): gut-liver-heart crosstalk","volume":"15","author":"Yang","year":"2023","journal-title":"Nutrients"},{"key":"B81","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3748\/wjg.v27.i8.677","article-title":"G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment","volume":"27","author":"Yang","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jnutbio.2008.05.013","article-title":"Regulation of adipogenesis by medium-chain fatty acids in the absence of hormonal cocktail","volume":"20","author":"Yang","year":"2009","journal-title":"J. Nutr. Biochem."},{"key":"B83","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.7150\/thno.35186","article-title":"Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer","volume":"9","author":"Yang","year":"2019","journal-title":"Theranostics"},{"key":"B84","doi-asserted-by":"publisher","first-page":"969757","DOI":"10.3389\/fmicb.2022.969757","article-title":"Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patients","volume":"13","author":"Yang","year":"","journal-title":"Front. Microbiol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41401-022-00860-3","article-title":"Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis","volume":"43","author":"Yang","year":"","journal-title":"Acta Pharmacol. Sin."},{"key":"B86","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.aninu.2023.10.005","article-title":"Leucine regulates lipid metabolism in adipose tissue through adipokine-mTOR-SIRT1 signaling pathway and bile acid-microbe axis in a finishing pig model","volume":"16","author":"Yin","year":"2024","journal-title":"Anim. Nutr."},{"key":"B87","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.3390\/ijms25084387","article-title":"Alteration of gut microbiota composition in the progression of liver damage in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"25","author":"Zazueta","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e2104373","DOI":"10.1002\/advs.202104373","article-title":"Multiomics analysis reveals the impact of microbiota on host metabolism in hepatic steatosis","volume":"9","author":"Zeybel","year":"2022","journal-title":"Adv. Sci. (Weinh)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1053\/j.gastro.2020.02.033","article-title":"TMAVA, a metabolite of intestinal microbes, is increased in plasma from patients with liver steatosis, inhibits gamma-butyrobetaine hydroxylase, and exacerbates fatty liver in mice","volume":"158","author":"Zhao","year":"2020","journal-title":"Gastroenterology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1038\/s41467-023-41061-8","article-title":"Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARalpha nucleus-cytoplasm shuttling","volume":"14","author":"Zhong","year":"2023","journal-title":"Nat. Commun."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","article-title":"Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.3390\/nu6072552","article-title":"The effects of choline on hepatic lipid metabolism, mitochondrial function and antioxidative status in human hepatic C3A cells exposed to excessive energy substrates","volume":"6","author":"Zhu","year":"2014","journal-title":"Nutrients"},{"key":"B93","doi-asserted-by":"publisher","first-page":"16733","DOI":"10.3390\/ijms242316733","article-title":"A high-fat diet increases the characteristics of gut microbial composition and the intestinal damage associated with non-alcoholic fatty liver disease","volume":"24","author":"Zhu","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1703547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:25:43Z","timestamp":1782966343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1703547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":93,"alternative-id":["10.3389\/fmolb.2026.1703547"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2026.1703547","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1703547"}}